Ofatumumab

BNF:
8.2.3
Status:
Do Not Prescribe (DNP), Red
Decision Date:
July 2015
 

Comments

RED1,2,3: NICE TA344: ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia.

RED1,2,3,8: NICE TA699: Ofatumumb for treating relapsing multiple sclerosis. (Decision date - June 2021)

DO NOT PRESCRIBE (DNP)6:NICE TA469 - idelalisib with ofatumumab for treating chronic lymphocytic leukaemia. (Terminated appraisal) (Decision date  - September 2017)

DO NOT PRESCRIBE (DNP)6: NICE TA470: ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia. (Terminated appraisal) (Decision date - Sep 2017)

NHSE is the responsible commissioner.

Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app